Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

AnaBios, Sanofi ink atrial fibrillation pact
April 2018
SHARING OPTIONS:

SAN DIEGO—AnaBios has joined forces with Sanofi for the development of a new treatment for atrial fibrillation, specifically compounds that will modulate a novel cardiac ion channel target. Under the terms of the agreement, AnaBios will gain development and commercialization rights to a family of compounds, though no financial details were released.
 
“Our new partnership with Sanofi, a global healthcare leader, validates the tremendous accomplishments of AnaBios in developing a human tissue- and cell-based technology for accurately predicting human clinical responses at an early development stage,” said Andre Ghetti, CEO of AnaBios. “We will employ our CardioPRIME technology to optimize the efficacy and safety of this novel class of molecules for the potential treatment of atrial fibrillation, a condition which affects over 33 million patients worldwide and remains difficult to treat.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2018 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.